As digital therapeutics grow in scope and application, regulatory scrutiny is sharpening, emphasising the importance of evidence and clear clinical claims for these software products designed to treat specific conditions.
Digital therapeutics are software products designed to do the work of treatment, not merely to support healthier habits. According to the FDA, they sit within a broader digital health field that also includes wearables, telehealth and health information technology, but the key difference is whether the software is intended for a medical purpose and therefore needs regulatory scrutiny.
That distinction matters because a digital therapeutic, often shortened to DTx, is meant to address a defined condition with a structured intervention. The European Data Protection Supervisor says these products are evidence-based software tools that can deliver approaches such as cognitive behavioural therapy or coaching programmes, while the FDA describes software intended to diagnose, treat or prevent disease as a form of medical device software.
In practice, that puts digital therapeutics in a different category from ordinary health and wellness apps. A general app may track sleep, count steps or encourage mindfulness, but a regulated therapeutic is cleared for a specific indication and is expected to show clinical benefit in trial data. In Australia, the Therapeutic Goods Administration says such products are a type of software-based medical device and must be included in the Australian Register of Therapeutic Goods before they can be supplied.
The range of uses is expanding. Examples cited in the source material include insomnia programmes, support for substance use disorder, attention-training tools for children with ADHD, guided exercise for chronic pain, coaching for diabetes and cardiometabolic conditions and some mental health uses alongside therapy or medication. Even so, the evidence can vary widely from one product to another, so regulatory clearance should be treated as the starting point rather than the final word.
The practical questions for patients are straightforward. What condition is the product approved to treat? Has it been tested in people like you? Is it meant to replace existing care or work alongside it? Who can see the data it collects? The FDA’s policy tools are designed to help developers decide whether software crosses the line into a regulated medical device, which underlines how closely intended use and real-world function are linked.
For clinicians and patients alike, the lesson is to read the claims carefully. A digital therapeutic is not just a health app with a medical-sounding label; it is a regulated intervention with a narrow purpose and a higher evidential bar. If the word “clinically proven” appears on the package, it is worth checking what was proven, in whom and under what conditions before relying on it.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
